10:31:57 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-08-14 Kvartalsrapport 2024-Q2
2024-03-07 X-dag ordinarie utdelning DEMANT 0.00 DKK
2024-03-06 Årsstämma 2024
2024-02-06 Bokslutskommuniké 2023
2023-08-15 Kvartalsrapport 2023-Q2
2023-03-09 X-dag ordinarie utdelning DEMANT 0.00 DKK
2023-03-08 Årsstämma 2023
2023-02-07 Bokslutskommuniké 2022
2022-08-16 Kvartalsrapport 2022-Q2
2022-03-11 X-dag ordinarie utdelning DEMANT 0.00 DKK
2022-03-10 Årsstämma 2022
2022-02-08 Bokslutskommuniké 2021
2021-08-12 Kvartalsrapport 2021-Q2
2021-03-08 X-dag ordinarie utdelning DEMANT 0.00 DKK
2021-03-05 Årsstämma 2021
2021-02-09 Bokslutskommuniké 2020
2020-08-17 Kvartalsrapport 2020-Q2
2020-03-11 X-dag ordinarie utdelning DEMANT 0.00 DKK
2020-03-10 Årsstämma 2020
2020-02-04 Bokslutskommuniké 2019
2019-08-14 Kvartalsrapport 2019-Q2
2019-03-20 X-dag ordinarie utdelning DEMANT 0.00 DKK
2019-03-19 Årsstämma 2019
2019-02-19 Bokslutskommuniké 2018
2018-08-15 Kvartalsrapport 2018-Q2
2018-03-23 X-dag ordinarie utdelning DEMANT 0.00 DKK
2018-03-22 Årsstämma 2018
2018-02-22 Bokslutskommuniké 2017
2017-08-14 Kvartalsrapport 2017-Q2
2017-05-09 Kvartalsrapport 2017-Q1
2017-03-28 X-dag ordinarie utdelning DEMANT 0.00 DKK
2017-03-27 Årsstämma 2017
2017-02-23 Bokslutskommuniké 2016
2016-11-10 Kvartalsrapport 2016-Q3
2016-08-17 Kvartalsrapport 2016-Q2
2016-05-25 Split DEMANT 1:5
2016-05-10 Kvartalsrapport 2016-Q1
2016-04-08 X-dag ordinarie utdelning DEMANT 0.00 DKK
2016-04-07 Årsstämma 2016
2016-03-01 Bokslutskommuniké 2015
2015-11-12 Kvartalsrapport 2015-Q3
2015-08-14 Kvartalsrapport 2015-Q2
2015-05-07 Kvartalsrapport 2015-Q1
2015-04-10 X-dag ordinarie utdelning DEMANT 0.00 DKK
2015-04-09 Årsstämma 2015
2015-02-26 Bokslutskommuniké 2014
2014-11-13 Kvartalsrapport 2014-Q3
2014-08-14 Kvartalsrapport 2014-Q2
2014-05-08 Kvartalsrapport 2014-Q1
2014-04-10 X-dag ordinarie utdelning DEMANT 0.00 DKK
2014-04-09 Årsstämma 2014
2014-02-27 Bokslutskommuniké 2013
2013-11-05 Kvartalsrapport 2013-Q3
2013-08-14 Kvartalsrapport 2013-Q2
2013-05-07 Kvartalsrapport 2013-Q1
2013-04-10 X-dag ordinarie utdelning DEMANT 0.00 DKK
2013-04-09 Årsstämma 2013
2013-02-26 Bokslutskommuniké 2012
2012-11-07 Kvartalsrapport 2012-Q3
2012-08-16 Kvartalsrapport 2012-Q2
2012-05-10 Kvartalsrapport 2012-Q1
2012-04-12 X-dag ordinarie utdelning DEMANT 0.00 DKK
2012-04-11 Årsstämma 2012
2012-02-29 Bokslutskommuniké 2011
2011-11-10 Kvartalsrapport 2011-Q3
2011-08-19 Kvartalsrapport 2011-Q2
2011-05-12 Kvartalsrapport 2011-Q1
2011-04-14 X-dag ordinarie utdelning DEMANT 0.00 DKK
2011-04-13 Årsstämma 2011
2010-11-16 Kvartalsrapport 2010-Q3
2010-04-08 X-dag ordinarie utdelning DEMANT 0.00 DKK

Beskrivning

LandDanmark
ListaLarge Cap Copenhagen
SektorHälsovård
IndustriMedicinteknik
Demant är verksamt inom medicinteknik. Bolaget är specialiserat inom utveckling av hörapparater och hörslingor. Idag innehar bolaget verksamhet på global nivå där produkterna säljs under varierande varumärken. Produkterna nås via bolagets distributörer och försäljningskanaler. Utöver huvudverksamheten bedriver bolaget forskning inom diagnostik för mätning av hörselkvalitén. Bolaget grundades ursprungligen under 1904 och har sitt huvudkontor i Smörum.
2023-06-22 08:04:46

22.6.2023 08:04:43 CEST | Demant A/S | Inside information

Company announcement no 2023-10                                   22 June 2023

Divestment of Oticon Medical to Cochlear amended in scope

 

The amended transaction with Cochlear includes only CI business

BAHS business will remain with Demant for now, pending review of strategic options

Transaction remains subject to final approval by the CMA and other regulatory authorities

Now expect negative profit after tax from discontinued operations in 2023 of DKK 700-1,000 million (prev. DKK 100-200 million), including non-cash write-downs of assets related to the CI business

 

Following dialogues with regulatory authorities and today’s final report published by the UK Competition and Markets Authority (CMA), Demant and Cochlear Limited have agreed to amend the scope of the original transaction, involving the divestment of Demant’s Hearing Implants business, Oticon Medical, to Cochlear Limited. The amended transaction only involves Demant’s cochlear implants (CI) business, whereas the bone anchored hearing systems (BAHS) business is no longer part of the transaction and will thus remain with Demant for now, pending a review of strategic options.

 

Today, the CMA has issued its final report, concluding that the original transaction may be expected to result in a substantial lessening of competition (SLC) in the supply of bone conduction solutions in the UK. This is in line with the CMA’s provisional findings dated 20 April 2023. The CMA has found that a partial prohibition of the original transaction, preventing the sale of the BAHS business to Cochlear, is an effective remedy to comprehensively address the SLC. This finding is subject to final approval by the CMA and their oversight of the separation of the CI and BAHS businesses.

 

“Following the final report from the UK competition authorities, we have concluded that there is now no viable path to obtain all necessary regulatory approvals for the full divestment of our Hearing Implants business to Cochlear. Consequently, we have agreed on an amended transaction, which only includes the CI business, and we are happy that a global leader in implantable solutions for hearing loss, Cochlear, remains committed to servicing Oticon Medical’s existing cochlear implant patients now and in the future,” says Søren Nielsen, President & CEO of Demant and continues:

 

“With the BAHS business no longer being part of the transaction with Cochlear, we remain fully committed to operating and further developing this business to continue serving all our BAHS customers and patients. The BAHS business is growing and delivering positive results, making for a solid starting point for a strategic review of future options.”

 

Demant’s decision to exit Hearing Implants, including the BAHS business, still stands, and for accounting purposes, we will thus continue to report the entire Hearing Implants business area as a discontinued operation.

 

Financial impact

Due to the amended scope, no consideration will be paid as part of the transaction. The transaction is expected to close before the end of 2023, however subject to regulatory approvals by the CMA, the Australian Competition and Consumer Commission (ACCC) and the European Commission (EC). This includes oversight of the separation of the CI and BAHS businesses by the CMA. The review of strategic options relating to the BAHS business is not expected to be complete until after closing of the transaction with Cochlear.

 

As a result of the amendment to the transaction, we will incur non-recurring, non-cash costs of DKK 600-800 million. These costs comprise write-downs of assets related to the CI business and will be recognised in H1 2023 as part of discontinued operations. Profit after tax of discontinued operations will also continue to include the operating activities of both the BAHS business and the CI business (until closing), which are still expected to contribute negatively by DKK 100-200 million in total in 2023. The contribution of the BAHS business is expected to be positive.

 

For 2023 as a whole, we now expect total profit after tax from discontinued operations to be negative by DKK 700-1,000 million (previously DKK 100-200 million). There are no other impacts on the Group’s outlook for 2023.

 

 

Further information:

Søren Nielsen, President & CEO

Phone +45 3917 7300

www.demant.com

Other contacts:

René Schneider, CFO

Mathias Holten Møller, Head of Investor Relations

Trine Kromann-Mikkelsen, VP Corporate Communication & Sustainability

About Demant A/S

Demant is a world-leading hearing healthcare group that offers solutions and services to help people with hearing loss connect with the world around them. In every aspect, from hearing devices, hearing implants, diagnostics to audio and video solutions and hearing care all over the world, Demant is active and engaged. Our innovative technologies and know-how help improve people’s health and hear-ing. We create life-changing differences through hearing health.

Attachments